{
  "content": "Between randomization and day 28, 70 of 258 patients in the amiodarone group (27.1 percent) had spontaneous conversion, as compared with 59 of 244 patients in the sotalol group (24.2 percent, P=0.45) and 1 of 132 patients in the placebo group (0.8 percent, P<0.001 for the comparison with both amiodarone and sotalol). The remainder underwent DC cardioversion on or near day 28, which was unsuccessful in 27.7 percent of the patients in the amiodarone group, 26.5 percent in the sotalol group, and 32.1 percent in the placebo group (P=0.54). The total rate of conversion was 79.8 percent in the amiodarone group, as compared with 79.9 percent in the sotalol group (P=0.98) and 68.2 percent in the placebo group (P=0.01 for the comparison with both amiodarone and sotalol)",
  "source": "https://www.nejm.org/doi/full/10.1056/NEJMoa041705",
  "chunk_id": "b32c89f6-c0e1-46ae-bda0-43c6d8a53c77",
  "similarity_score": 0.4313039779663086,
  "query": "amiodarone cardioversion rhythm control atrial fibrillation conversion rate success",
  "rank": 38,
  "title": "Amiodarone versus Sotalol for Atrial Fibrillation",
  "authors": "Bramah N. Singh, M.D., D.Sc., Steven N. Singh, M.D., Domenic J. Reda, Ph.D., X. Charlene Tang, M.D., Ph.D., Becky Lopez, R.N., Crystal L. Harris, Pharm.D., Ross D. Fletcher, M.D., Satish C. Sharma, M.D., J. Edwin Atwood, M.D., Alan K. Jacobson, M.D., H. Daniel Lewis, Jr., M.D., Dennis W. Raisch, Ph.D., Michael D. Ezekowitz, M.B., Ch.B., Ph.D.",
  "year": "2005",
  "journal": "New England Journal of Medicine",
  "reference": "Singh, B. N., Singh, S. N., Reda, D. J., Tang, X. C., Lopez, B., Harris, C. L., Fletcher, R. D., Sharma, S. C., Atwood, J. E., Jacobson, A. K., Lewis, H. D. Jr., Raisch, D. W., & Ezekowitz, M. D. (2005). Amiodarone versus sotalol for atrial fibrillation. New England Journal of Medicine, 352(18), 1861-1872. https://doi.org/10.1056/NEJMoa041705",
  "doi": "10.1056/NEJMoa041705",
  "chunk_index": 29,
  "total_chunks": 127,
  "retrieved_at": "2025-07-24T22:33:15.199189"
}